Novadip Biosciences recently received an infusion of €40 million (~USD $40 million) in investments, increasing its total funding to €88 million. The Belgium-based company will use the capital to develop a new class of adipose-derived stem cell (ASC) tissue regeneration platforms designed to accelerate bone union and healing through single-treatment cures.
